SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) — Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part…Read More
Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
